359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

by Hui Yang, Stephane Champiat, Ramaswamy Govindan, Ravi Salgia, Fiona Blackhall, Everett Vokes, Michael Boyer, Marie-Anne Damiette Smit, Melissa Johnson, Hossein Borghaei, Luis Paz-Ares Rodrigues, Rene Boosman, Horst-Dieter Hummel, W Victoria Lai, Hibiki Udagawa, Anne Chiang, Christine Hann, Mukul Minocha, Nooshin Hashemi-Sadraei, Aditya Shetty, Taofeek Owonikoko
Published 2020-11-01